Serum Institute of India and Oxford University on COVID-19 vaccine trials: encouraging results and ready for production

Serum Institute of India started the new trial on COVID-19 vaccine. The institute got the permission of the Oxford University to carry out the studies and gained the permission to produce the final vaccine, once it gets ready.

On the end of July, trials of COVID-19 vaccine being developed by AstraZeneca and Oxford University showing encouraging results. Serum Institute of India (SII) declared the institute will apply for a licence from the Indian regulator to start clinical trials.

 

Serum Institute of India on COVID-19 vaccine: the licence of manufacture once it is ready

Oxford University appears to have developed a safe COVID-19 vaccine and that induces a strong immune response within the body. After the first phase of human trials against the coronavirus pandemic, scientists announced that the disease has already infected over 1.45 crore people across the world.

SII (Serum Institute of India) is the largest vaccine manufacturer in the world. Oxford University and its partner, AstraZeneca chose it to manufacture the vaccine once it gets ready. However, the Pune-based SII had said that it will start manufacturing the vaccine even before the final nod.

SII Chief Executive Officer Adar Poonawalla stated that the trials on COVID-19 future vaccine have shown promising results and we are extremely happy about it. Again, “We will apply for the licensure trials to the Indian regulator in a week’s time. As soon as they grant us permission, we will begin with the trials for the vaccine in India.”

The idea of the Serum Institute of India is also to start manufacturing the vaccine in large volumes, very soon.

 

COVID-19 vaccine: What are the results?

AstraZeneca declared that the interim results from the ongoing Phase I/II COV001 trial, led by Oxford University showed that the vaccine was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.

As part of phase I clinical trial and results, five UK hospitals administered doses of the ‘vaccine’ to 1,077 healthy adults aged between 18 and 55 between April and May. The results show they induced strong antibody and T-cell immune responses for up to 56 days after they were given.

 

Serum Institute of India, is the vaccine almost ready?

Findings only report that results are promising, but experts feel it is too soon to know if this is enough to offer protection. Scientists behind the trials found the response could be even greater after a second dose.

Professor Andrew Pollard, Chief investigator of the Oxford Vaccine Trial at Oxford University and co-author of the study, reported that the immune responses observed are in line with what previous animal studies have shown, i.e. protection against the SARS-CoV-2 virus. Although, research must go on and the rigorous clinical trial programme must be carried on.

 

READ ALSO

Made in Italy COVID-19 vaccine: Spallanzani institute is on its way! (Italian)

WHO and UNICEF: fewer children have access to life-saving vaccines worldwide due to the pandemic

Vaccine for coronavirus? Test begin in September, results on 2021 New Year’s Eve

First case of meningitis associated with SARS-CoV-2. A case report from Japan

 

SOURCES

SII (Serum Institute of India official website)

First Post

Comments are closed.